efficacy

Gaboxadol in Fragile X Syndrome: A 12-Week Randomized, Double-Blind, Parallel-Group, Phase 2a Study

Authors: Dejan B Budimirovic, Kelli C Dominick, Lidia V Gabis, Maxwell Adams, Mathews Adera, Linda Huang, Pamela Ventola, Nicole R Tartaglia, Elizabeth Berry-Kravis

Journal: Frontiers in Pharmacology

Year Published: 2021

Background: Fragile X syndrome (FXS), the most common single-gene cause of intellectual disability and autism spectrum disorder (ASD), is caused by a >200-trinucleotide repeat expansion in the 5′ untranslated region of the fragile X mental retardation […]

Adaptive behavior in autism: Minimal clinically important differences on the Vineland‐II

Authors: C H Chatham, K I Taylor, T Charman, X Liogier D'ardhuy, E Eule, A Fedele, A Y Hardan, E Loth, L Murtagh, M Del Valle Rubido, A San Jose Caceres, J Sevigny, L Sikich, L Snyder, J E Tillmann, P E Ventola, K L Walton-Bowen, P P Wang, T Willgoss, F Bolognani

Journal: Autism Research

Year Published: 2018

Abstract: Autism Spectrum Disorder (ASD) is associated with persistent impairments in adaptive abilities across multiple domains. These social, personal, and communicative impairments become increasingly pronounced with development, and are present regardless of IQ. The Vineland Adaptive […]

Back to Publications